Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome.

Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, Ginger M, Frick A, DiPatrizio NV, Mackie K, Katona I, Piomelli D, Manzoni OJ.

Nat Commun. 2012;3:1080. doi: 10.1038/ncomms2045.

2.

Metabotropic glutamate receptors and fragile x mental retardation protein: partners in translational regulation at the synapse.

Ronesi JA, Huber KM.

Sci Signal. 2008 Feb 5;1(5):pe6. doi: 10.1126/stke.15pe6. Review.

PMID:
18272470
3.

Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome.

Dölen G, Bear MF.

J Physiol. 2008 Mar 15;586(6):1503-8. doi: 10.1113/jphysiol.2008.150722. Epub 2008 Jan 17. Review.

4.

Mechanism-based approaches to treating fragile X.

Dölen G, Carpenter RL, Ocain TD, Bear MF.

Pharmacol Ther. 2010 Jul;127(1):78-93. doi: 10.1016/j.pharmthera.2010.02.008. Epub 2010 Mar 18. Review.

PMID:
20303363
5.

Fragile X syndrome and targeted treatment trials.

Hagerman R, Lauterborn J, Au J, Berry-Kravis E.

Results Probl Cell Differ. 2012;54:297-335. doi: 10.1007/978-3-642-21649-7_17. Review.

6.

Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function.

Bassell GJ, Warren ST.

Neuron. 2008 Oct 23;60(2):201-14. doi: 10.1016/j.neuron.2008.10.004. Review.

7.

Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development.

Pop AS, Gomez-Mancilla B, Neri G, Willemsen R, Gasparini F.

Psychopharmacology (Berl). 2014 Mar;231(6):1217-26. Review.

PMID:
24232444
8.

Potential therapeutic interventions for fragile X syndrome.

Levenga J, de Vrij FM, Oostra BA, Willemsen R.

Trends Mol Med. 2010 Nov;16(11):516-27. doi: 10.1016/j.molmed.2010.08.005. Epub 2010 Sep 21. Review.

9.

The mGluR theory of fragile X mental retardation.

Bear MF, Huber KM, Warren ST.

Trends Neurosci. 2004 Jul;27(7):370-7. Review.

PMID:
15219735
10.

The pathophysiology of fragile X (and what it teaches us about synapses).

Bhakar AL, Dölen G, Bear MF.

Annu Rev Neurosci. 2012;35:417-43. doi: 10.1146/annurev-neuro-060909-153138. Epub 2012 Apr 5. Review.

11.

Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediated signalling in disorders associated with Intellectual Disability and Autism.

D'Antoni S, Spatuzza M, Bonaccorso CM, Musumeci SA, Ciranna L, Nicoletti F, Huber KM, Catania MV.

Neurosci Biobehav Rev. 2014 Oct;46 Pt 2:228-41. doi: 10.1016/j.neubiorev.2014.02.003. Epub 2014 Feb 15. Review.

PMID:
24548786
12.

Translating molecular advances in fragile X syndrome into therapy: a review.

Hagerman RJ, Des-Portes V, Gasparini F, Jacquemont S, Gomez-Mancilla B.

J Clin Psychiatry. 2014 Apr;75(4):e294-307. doi: 10.4088/JCP.13r08714. Review.

PMID:
24813413
13.

Synaptic regulation of protein synthesis and the fragile X protein.

Greenough WT, Klintsova AY, Irwin SA, Galvez R, Bates KE, Weiler IJ.

Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7101-6. Review.

14.

Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links.

Sokol DK, Maloney B, Long JM, Ray B, Lahiri DK.

Neurology. 2011 Apr 12;76(15):1344-52. doi: 10.1212/WNL.0b013e3182166dc7. Review.

15.

Fragile X: translation in action.

Bear MF, Dölen G, Osterweil E, Nagarajan N.

Neuropsychopharmacology. 2008 Jan;33(1):84-7. Epub 2007 Oct 17. Review.

16.

Fragile X Syndrome and Alzheimer's Disease: Another story about APP and beta-amyloid.

Malter JS, Ray BC, Westmark PR, Westmark CJ.

Curr Alzheimer Res. 2010 May;7(3):200-6. Review.

17.

Transcription, translation and fragile X syndrome.

Garber K, Smith KT, Reines D, Warren ST.

Curr Opin Genet Dev. 2006 Jun;16(3):270-5. Epub 2006 May 2. Review.

PMID:
16647847
18.

Taking STEPs forward to understand fragile X syndrome.

Goebel-Goody SM, Lombroso PJ.

Results Probl Cell Differ. 2012;54:223-41. doi: 10.1007/978-3-642-21649-7_12. Review.

19.

New insights into the molecular pathophysiology of fragile X syndrome and therapeutic perspectives from the animal model.

Busquets-Garcia A, Maldonado R, Ozaita A.

Int J Biochem Cell Biol. 2014 Aug;53:121-6. doi: 10.1016/j.biocel.2014.05.004. Epub 2014 May 14. Review.

PMID:
24831882
20.

Fragile X: a family of disorders.

Chonchaiya W, Schneider A, Hagerman RJ.

Adv Pediatr. 2009;56:165-86. doi: 10.1016/j.yapd.2009.08.008. Review. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk